University Research Foundation for Lysosomal Storage Disorders Report issue

Foundation

Organization Overview

First Clinical Trial
2009
NCT01031173
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

University Research Foundation for Lysosomal Storage Diseases, Inc.

Active Ingredients

Drugs in Other Trials (1)

agalsidase alfa (Replagal) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1